SMC accepts linagliptin (Trajenta®) for restricted use in the treatment of type 2 diabetes

Source: Scottish Medicines Consortium (SMC) Area: Evidence > Drug Specific Reviews The Scottish Medicines Consortium (SMC) has accepted linagliptin (Trajenta®) for restricted use within NHS Scotland for the treatment of type 2 diabetes, in the following scenarios:   as monotherapy in patients for whom both metformin and sulphonylureas are inappropriate due to contraindications or intolerance as combination therapy with a sulphonylurea and metformin when diet and exercise plus dual therapy does not provide adequate glycaemic control   The SMC is unable to recommend the use of linagliptin in combination with insulin as the economic case has not been demonstrated.   Please see the Detailed Advice accompanying the recommendation (see link below), for further information on the evidence on efficacy and safety, the clinical effectiveness issues and the health economic evidence considered by the SMC.   Linagliptin has already been accepted by SMC (746/11) for use in combination with metformin when diet and exercise plus ...
Source: NeLM - Drug Specific Reviews - Category: Drugs & Pharmacology Source Type: news